GSK plc (LSE/NYSE: GSK) and BELLUS Health Inc. (TSX/NASDAQ: BLU) today announced GSK has completed the acquisition of BELLUS, a biopharmaceutical company working to better the lives of patients suffering from refractory chronic cough (RCC), by way of a plan of arrangement in accordance with Section 192 of the Canada Business Corporations Act (the “Arrangement”). The Arrangement was approved by BELLUS’ shareholders on 16 June 2023.
Read MoreOTTAWA, ON, June 20, 2023 /CNW/ - The Patented Medicine Prices Review Board (PMPRB) launched a new 60-day Notice and Comment period today, encouraging stakeholders and interested members of the public to provide their input on new proposed Interim Guidance.
Read MoreQUÉBEC CITY, June 13, 2023 /PRNewswire/ - Feldan Therapeutics, a biopharmaceutical company that specializes in the development of treatments based on intracellular delivery of therapeutics, has announced the initial closing of a $16.5 million Series B investment. The funds will primarily be used to conduct clinical phases I/II for Feldan's FLD-103, an intralesional treatment against basal cell carcinoma (BCC), and to advance its pulmonary program to the preclinical stage.
Read MoreBoston, Massachusetts – June 5, 2023 – CQDM is delighted, at BIO2023, in the presence of Minister Fitzgibbon, Quebec’s Minister of the Economy, Innovation and Energy (MEIE) to announce that Merck Canada, has renewed its commitment to CQDM with $3.0M in funding to support the development of innovative technologies in biopharmaceutical research.
Read MoreMONTREAL and BOSTON, June 5, 2023 /CNW/ - Oncopole, Fonds de recherche du Québec - Santé (FRQS) cancer division, is proud to announce major investments that bolster its unique public-private partnership model dedicated to the fight against cancer. Building on its dynamism and ability to mobilize stakeholders in the life sciences community, Oncopole will continue to pursue its mission thanks to a $3 million reinvestment from founding partner Merck Canada.
Read MoreGrant recognizes CCfV's national leadership and Nova Scotian contribution to Canada's research capabilities, expected to attract top talent.
MISSISSAUGA, ON, May 31, 2023 /CNW/ - GSK announces a $1 million grant to strengthen the Canadian Center for Vaccinology (CCfV)'s position in the national infectious disease research landscape. The private funding will be a catalyst for growth of the Halifax-based centre, increasing employment opportunities and bolstering top-quality research and pandemic preparedness locally and nationally.
Read MoreMONTRÉAL, Aug. 17, 2021 /CNW Telbec/ - NuChem Sciences, a drug discovery in chemistry contract research organization (CRO) located in Montréal, today announced the acquisition of OmegaChem of Lévis, Québec. As a result of this transaction, the new group formed by the two companies becomes Canada's largest CRO in drug discovery in chemistry.
Read More
